These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34121453)

  • 1. Role of the CX
    Hamdan D; Robinson LA
    Am J Physiol Renal Physiol; 2021 Aug; 321(2):F121-F134. PubMed ID: 34121453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?
    Zhuang Q; Cheng K; Ming Y
    Curr Gene Ther; 2017; 17(6):442-452. PubMed ID: 29446734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease?
    Cormican S; Griffin MD
    Front Immunol; 2021; 12():664202. PubMed ID: 34163473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents.
    Poniatowski ŁA; Wojdasiewicz P; Krawczyk M; Szukiewicz D; Gasik R; Kubaszewski Ł; Kurkowska-Jastrzębska I
    Mol Neurobiol; 2017 Apr; 54(3):2167-2188. PubMed ID: 26927660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders.
    Pawelec P; Ziemka-Nalecz M; Sypecka J; Zalewska T
    Cells; 2020 Oct; 9(10):. PubMed ID: 33065974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure and Function of Ligand CX3CL1 and its Receptor CX3CR1 in Cancer.
    Lu X
    Curr Med Chem; 2022; 29(41):6228-6246. PubMed ID: 35770395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CX3CL1 Signaling in the Tumor Microenvironment.
    Conroy MJ; Lysaght J
    Adv Exp Med Biol; 2020; 1231():1-12. PubMed ID: 32060841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The deficiency of CX3CL1/CX3CR1 system ameliorates high fructose diet-induced kidney injury by regulating NF-κB pathways in CX3CR1-knock out mice.
    Yu YW; Li MX; Zhang ZY; Yu H
    Int J Mol Med; 2018 Jun; 41(6):3577-3585. PubMed ID: 29568873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human CD16+ monocytes promote a pro-atherosclerotic endothelial cell phenotype via CX3CR1-CX3CL1 interaction.
    Roy-Chowdhury E; Brauns N; Helmke A; Nordlohne J; Bräsen JH; Schmitz J; Volkmann J; Fleig SV; Kusche-Vihrog K; Haller H; von Vietinghoff S
    Cardiovasc Res; 2021 May; 117(6):1510-1522. PubMed ID: 32717023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shedding light on the role of CX3CR1 in the pathogenesis of schizophrenia.
    Chamera K; Szuster-Głuszczak M; Basta-Kaim A
    Pharmacol Rep; 2021 Aug; 73(4):1063-1078. PubMed ID: 34021899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway.
    Liu P; Liang Y; Jiang L; Wang H; Wang S; Dong J
    Int J Oncol; 2018 Oct; 53(4):1544-1556. PubMed ID: 30066854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation and function of CX3CR1 and its ligand CX3CL1 in kidney disease.
    von Vietinghoff S; Kurts C
    Cell Tissue Res; 2021 Aug; 385(2):335-344. PubMed ID: 34009468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.
    Subbarayan MS; Joly-Amado A; Bickford PC; Nash KR
    Pharmacol Ther; 2022 Mar; 231():107989. PubMed ID: 34492237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of CX3CL1/CX3CR1 Signaling Axis Activity in Osteoporosis.
    Wojdasiewicz P; Turczyn P; Dobies-Krzesniak B; Frasunska J; Tarnacka B
    Mediators Inflamm; 2019; 2019():7570452. PubMed ID: 31780870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathepsin S contributes to microglia-mediated olfactory dysfunction through the regulation of Cx3cl1-Cx3cr1 axis in a Niemann-Pick disease type C1 model.
    Seo Y; Kim HS; Kang I; Choi SW; Shin TH; Shin JH; Lee BC; Lee JY; Kim JJ; Kook MG; Kang KS
    Glia; 2016 Dec; 64(12):2291-2305. PubMed ID: 27687148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis.
    Wojdasiewicz P; Poniatowski LA; Kotela A; Deszczyński J; Kotela I; Szukiewicz D
    Arch Immunol Ther Exp (Warsz); 2014 Oct; 62(5):395-403. PubMed ID: 24556958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis.
    Szukiewicz D
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between the CX3CL1/CX3CR1 Axis and Inflammatory Signaling Pathways in Tissue Injury.
    Zhuang Q; Ou J; Zhang S; Ming Y
    Curr Protein Pept Sci; 2019; 20(8):844-854. PubMed ID: 30843484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fractalkine/CX3CR1 is involved in the cross-talk between neuron and glia in neurological diseases.
    Luo P; Chu SF; Zhang Z; Xia CY; Chen NH
    Brain Res Bull; 2019 Mar; 146():12-21. PubMed ID: 30496784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemokine CX3CL1 (Fractalkine) Signaling and Diabetic Encephalopathy.
    Wątroba M; Grabowska AD; Szukiewicz D
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.